FDA Updates Stribild Labeling
On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information.
The updated labeling for Stribild is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on Stribild
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Clinical Trials | Department of Health | Health | HIV AIDS | Infectious Diseases | Truvada | Viread | Websites